单位:[1]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China[2]Department of Pain Relief, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’sClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China[3]Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’sClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China[4]Department of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China[5]Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital andInstitute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China[6]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,China外科学系华中科技大学同济医学院附属同济医院泌尿外科[7]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,China肿瘤科华中科技大学同济医学院附属同济医院
National Natural Science Foundation of
China (grant no. 82073356); the Beijing-Tianjin-Hebei Basic Research Cooperation Special Project (grant no. 22JCZXJC00180); the Science & Technology
Development Fund of Tianjin Education Commission for Higher Education
(grant no. 2021ZD034); and the Bethune$ Tumor Radiotherapy Translational
Medicine Research Fund (grant no. FLZH202108).
第一作者单位:[1]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer,Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China[4]Department of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China[7]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,China
推荐引用方式(GB/T 7714):
Zhang Yuhan,Hu Junyi,Ji Kai,et al.CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells[J].CELL REPORTS MEDICINE.2023,4(8):doi:10.1016/j.xcrm.2023.101151.
APA:
Zhang Yuhan,Hu Junyi,Ji Kai,Jiang Shengpeng,Dong Yang...&Tao Zhen.(2023).CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells.CELL REPORTS MEDICINE,4,(8)
MLA:
Zhang Yuhan,et al."CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells".CELL REPORTS MEDICINE 4..8(2023)